HGFR/c-MET Antibody (SP44)

Product Discontinued

HGFR/c-MET Antibody (SP44) Summary

• Immunogen: Synthetic peptide corresponding to C-terminus of human c-met protein
• Localization: Membrane
• Isotype: IgG
• Clonality: Monoclonal
• Host: Rabbit
• Gene: MET
• Purity: Protein A purified

Applications/Dilutions

• Dilutions:
  • Immunohistochemistry 1:10-1:500
  • Immunohistochemistry-Paraffin 1:50
  • Western Blot 1:500-1:1000
• Application Notes: This c-Met Antibody (SP44) is useful for Western blot and Immunohistochemistry on paraffin-embedded sections. In WB a band can be seen at ~145 kDa. For IHC-P: Antigen retrieval can be performed using a citrate process.
• Theoretical MW: 145 kDa.
  Disclaimer note: The observed molecular weight of the protein may vary from the listed predicted molecular weight due to post translational modifications, post translation cleavages, relative charges, and other experimental factors.
• Control:

  HepG2 Whole Cell Lysate

Reactivity Notes

Human

Packaging, Storage & Formulations

• Storage: Store at 4C. Do not freeze.
• Buffer: PBS (pH 7.6) and 1.0% BSA
• Preservative: 0.099% Sodium Azide
• Purity: Protein A purified

Notes

For a positive control use Breast carcinoma.

Alternate Names for HGFR/c-MET Antibody (SP44)

• AUTS9
• cMET
• c-MET
• EC 2.7.10
• EC 2.7.10.1
• hepatocyte growth factor receptor
• HGF R
• HGF receptor
• HGF/SF receptor
• HGFR
• Met (c-Met)
• met proto-oncogene (hepatocyte growth factor receptor)
• met proto-oncogene tyrosine kinase
• MET
• oncogene MET
• Proto-oncogene c-Met
• RCCP2
• Scatter factor receptor
• SF receptor
• Tyrosine-protein kinase Met

Background

Met is a receptor protein-tyrosine kinase (RPTK) for hepatocyte growth factor (HGF), which is a multifunctional cytokine controlling cell growth, morphogenesis, and motility. Met overexpression has been identified in a variety of human cancers (1). Met kinase domain possesses unique features that distinguish met from other members of the src family of protein tyrosine kinases. These results also demonstrate that the product of the activated met gene is a fusion protein and that the amino terminal end of this fusion protein exhibits homology to laminin B1 (2). Data suggest that RanBP9, functioning as an adaptor protein for the Met tyrosine kinase domain, can augment the HGF-Met signaling pathway and that RanBP9 overexpression may cause constitutive activation of the Ras signaling pathway (1). Hereditary papillary renal carcinoma (HPRC) is a recently recognized form of inherited kidney cancer Results suggest that missense mutations located in the MET proto-oncogene lead to constitutive activation of the Met protein and papillary renal carcinomas (3)

Limitations

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.

Publications for HGFR/c-MET Antibody (NBP1-49808)(1)

Publication using NBP1-49808

• Inanc M, Ozkan M, Karaca H et al. Cytokeratin 5/6, c-Met expressions, and PTEN loss prognostic indicators in triple-negative breast cancer. Med Oncol 2014-01-01 [PMID: 24326984] (IF/IHC, Human)

Bioinformatics

• Gene Symbol: MET
• Entrez:
  • 4233(Human)
• Uniprot:
  • P08581()